281
Views
14
CrossRef citations to date
0
Altmetric
Eco/Toxicology

Acrylamide disrupts the steroidogenic pathway in Leydig cells: possible mechanism of action

&
Pages 235-246 | Received 05 May 2017, Accepted 22 Mar 2018, Published online: 20 Apr 2018
 

ABSTRACT

Acrylamide-treated Leydig cells were tested for cytotoxicity, testosterone secretion, 3′,5′-cyclic adenosine monophosphate production, and gene and protein expression of steroidogenic genes and transcription factors. Reverse-transcriptional real-time polymerase chain reaction and western blot analysis revealed that acrylamide disrupts mRNA and protein expression of steroidogenic markers, including luteinizing hormone receptor, steroidogenic acute regulatory protein, cholesterol side-chain cleavage enzyme, 3β-hydroxy dehydrogenase, and 17β-hydroxy dehydrogenase. Further, transcription levels of the key regulator transcription factors, steroidogenic factor-1, GATA binding protein-4, and nerve growth factor IB, were evaluated. Acrylamide induced cytotoxicity and decreased testosterone and 3′,5′-cyclic adenosine monophosphate secretion by altering the rate-limiting steps in Leydig cell steroidogenesis.

Disclosure statement

The authors declare that there are no conflicts of interest.

Additional information

Funding

This work was supported by the Istanbul University Scientific Research Projects [project number 47199], [project number 45799].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.